Yearly Archives: 2018

Home/2018

MedTech Access – Leaders Forum in Berlin 3-5 December

2018-12-07T17:35:43+02:00December 7th, 2018|Categories: Uncategorised|

A CE-mark is not enough to bring medical device products to the market. Claudia Wild, EUnetHTA member, talks on synergies between medical device regulation (MDR) clinical evidence demand and synergies with HTA processes at the MedTech Access Leaders Forum in Berlin Dec 3-5, 2018. Read more about the event here: https://lnkd.in/gGnXfp5

New publication: Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries.

2018-12-04T15:59:31+02:00December 4th, 2018|Categories: Cancer, Nordic Health Registers, Pharmacoepidemiology|

By pooling Nordic health data on medical devices & pharmaceuticals, and analyzing it on the micro-level, we tap into the full potential of big data. The Nordic health registers cover 26 mill. people from birth to death. Read about our most recent safety study, pooling data from 4 Nordic countries, here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773955/ 

ApHER at ISPOR Barcelona 2018: Cost of multiple sclerosis

2018-11-16T13:57:43+02:00November 16th, 2018|Categories: Diseases of the nervous system, Health Economics, Nordic Health Registers|

ApHER participated at ISPOR Europe 2018 and presented a study “COSTS OF MULTIPLE SCLEROSIS IN DENMARK: A REGISTER BASED STUDY”. The unique registers in Denmark allow us to include in the study all individuals with Multiple Sclerosis (MS) in Denmark.  All Individuals with MS in 2014 were ascertained and characterized by treatment from the Danish health [...]

Danish Cancer Research Days 30-31 August 2018

2018-11-16T13:58:46+02:00September 28th, 2018|Categories: Cancer, Health Economics|

ApHER participated at the cancer research days presenting the CEDAR study, a nationwide, observational study including all patients living with cancer of the lung, breast, bladder, ovary, and prostate as of 31st December 2005 and all patients first-time diagnosed from then up to 31st December 2015. Patients are followed from date of first diagnosis until death [...]

Earth Overshoot Day – August 1st 2018

2018-08-03T15:22:27+02:00August 3rd, 2018|Categories: Environmental Economics, Uncategorised|

It’s our party. But it ends today. By Aug 1st the global natural resources available for 2018 are spent. Anything beyond this is excess consumption. ApHER marks Earth Overshoot Day by venturing into projects improving the environment that surrounds us. Protecting our health. What can you do to #movethedate?  Cancel your flight and use Skype. Use your [...]

New study: Many patients go for years without seeing a sclerosis doctor

2018-09-28T14:14:20+02:00April 6th, 2018|Categories: Diseases of the nervous system, Health Economics, Nordic Health Registers, Pharmacoepidemiology|

Six out of ten of the sclerosis patients who are not in disease-modifying treatment do not attend annual follow-ups. This means that the patients do not receive the symptom management or rehabilitation they need. These results come from a new study by ApHER conducted in collaboration with the Danish Multiple Sclerosis Society, presented by Prof. Anders Green [...]

It is a good investment to prevent the development of lifestyle diseases such as diabetes

2018-09-28T13:44:19+02:00March 31st, 2018|Categories: Endocrine, nutritional and metabolic diseases, Health Economics, Nordic Health Registers|

A poorly regulated diabetes patient is costly for both the public healthcare system and the private insurance companies. In a recent cost-effectiveness study of the LIVA platform ApHER concludes that there is a desirable investment return by managing diabetes patients digitally through online lifestyle coaching. Read the article at LIVA Healthcare here.